Vitrolife (Q1 review): Fx-headwind but solid profitability - Redeye

Vitrolife reported softer revenues relative to our estimates, as we had projected a more modest fx-impact. However, despite missing our sales projection by ~8%, gross and EBITDA margins exceeded our forecasts, reflecting a favourable product mix and solid cost control. Following a sharp share price recovery in recent weeks, the stock now trades at ~14 2026e EV/EBITDA, which we view as broadly fair given the relatively low estimate risk and the company's mature growth profile.

Länk till analysen i sin helhet: https://www.redeye.se/research/1160027/vitrolife-q1-review-fx-headwind-but-solid-profitability?utm_source=finwire&utm_medium=RSS